Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Cole, A., Towse, A. and Zamora, B.

Briefing
May 2019

Sign Up for OHE Updates

Why not sign up for our email updates? Around once or twice a week we will send you a round-up of the latest news, events and publications from OHE.

I'm already signed up    No thanks

Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we outline the major issues including the potential benefits of IBP, potential draw-backs, and considerations for implementation. We then ask for your views.
 
To submit your thoughts, please access the survey which accompanies the Discussion Paper. 
 
Consultation closing date: Monday 24th June 2019.